AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9436798 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate PVL
Number of subjects: 66
Study 9436798 — intervention group
Group type: COMPARATOR
Intervention: Control group (preterm infants without PVL)
Number of subjects: 66
Study 8430681 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg twice a day)
Number of subjects: 60
Study 8430681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8430681 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 60
Study 3315581 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC (30U in 4 to 5 minutes)
Number of subjects: 86
Study 3315581 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase (1.5 X 10(6) U in 60 minutes)
Number of subjects: 86
Study 3315581 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC
Number of subjects: 86
Study 3315581 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 86
Study 3315581 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 86
Study 29178491 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrolizumab (0.3 to 10 mg/kg, administered intravenously or subcutaneously)
Number of subjects: 38
Study 29178491 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Number of subjects: 38
Study 29178491 — intervention group
Group type: EXPERIMENTAL
Intervention: PK and PD profiles predicted by the model
Number of subjects: 38
Study 27589795 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Nitrate Diet (HND)
Number of subjects: 7
Study 27589795 — intervention group
Group type: COMPARATOR
Intervention: Control Diet (CD)
Number of subjects: 7
Study 26184257 — intervention group
Group type: EXPERIMENTAL
Intervention: HEPA filtration for 21 days
Number of subjects: 20
Study 26184257 — intervention group
Group type: COMPARATOR
Intervention: Sham filtration for 21 days
Number of subjects: 20
Study 26184257 — intervention group
Group type: EXPERIMENTAL
Intervention: HEPA filtration
Number of subjects: 20
Study 22809293 — intervention group
Group type: EXPERIMENTAL
Intervention: Portrayal of negative consequences of alcohol use
Number of subjects: 108
Study 22809293 — intervention group
Group type: EXPERIMENTAL
Intervention: Portrayal of positive consequences of alcohol use
Number of subjects: 108
Study 22809293 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exposure to any program)
Number of subjects: 108
Study 21346218 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematoma expansion (HE) definitions
Number of subjects: 531
Study 21346218 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute growth cutoffs
Number of subjects: 531
Study 21346218 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute growth definition
Number of subjects: 531
Study 19032127 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy
Number of subjects: 0
Study 19032127 — intervention group
Group type: COMPARATOR
Intervention: Fixed combination treatments (budesonide/formoterol and salmeterol/fluticasone with terbutaline as needed)
Number of subjects: 0
Study 16606471 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive 'step-up approach' starting with drainage followed by videoscopic assisted retroperitoneal debridement (VARD)
Number of subjects: 88
Study 16606471 — intervention group
Group type: COMPARATOR
Intervention: Maximal necrosectomy by laparotomy
Number of subjects: 88
Study 16606471 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures followed by continuous postoperative lavage (CPL)
Number of subjects: 88
Study 12932111 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D brain map using the 3D-SSP program
Number of subjects: 25
Study 12932111 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 age-matched cases)
Number of subjects: 25
Study 10942742 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD
Number of subjects: 288
Study 10942742 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone/Metoprolol
Number of subjects: 288
Study 8737097 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose warfarin and aspirin
Number of subjects: 0
Study 8737097 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 8466726 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 1.25 mg twice daily
Number of subjects: 595
Study 8466726 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg twice daily
Number of subjects: 595
Study 8466726 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine plus spirapril 3 mg
Number of subjects: 595
Study 8466726 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine plus pindolol 5 mg
Number of subjects: 595
Study 8466726 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-recorded blood pressure in a subgroup of 45 patients
Number of subjects: 595
Study 8466726 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with isradipine
Number of subjects: 595
Study 8466726 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-effects related to treatment
Number of subjects: 595
Study 3740382 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine
Number of subjects: 28
Study 3740382 — intervention group
Group type: COMPARATOR
Intervention: pethidine
Number of subjects: 28
Study 3740382 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine and pethidine
Number of subjects: 28
Study 29749663 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT
Number of subjects: 45
Study 29749663 — intervention group
Group type: EXPERIMENTAL
Intervention: RT
Number of subjects: 45
Study 29749663 — intervention group
Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 45
Study 29749663 — intervention group
Group type: COMPARATOR
Intervention: CG
Number of subjects: 45
Study 26340058 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed reminders sent to GPs every 4 months regarding patients who had not performed scheduled faecal occult blood test (FOBT) screening.
Number of subjects: 144
Study 26340058 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reminders).
Number of subjects: 144
Study 26340058 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed reminders sent to GPs.
Number of subjects: 144
Study 25668166 — intervention group
Group type: EXPERIMENTAL
Intervention: Target temperature management at 33 °C
Number of subjects: 939
Study 25668166 — intervention group
Group type: COMPARATOR
Intervention: Target temperature management at 36 °C
Number of subjects: 939
Study 22742205 — intervention group
Group type: EXPERIMENTAL
Intervention: IV montelukast 7 mg
Number of subjects: 242
Study 22742205 — intervention group
Group type: EXPERIMENTAL
Intervention: IV montelukast 14 mg
Number of subjects: 242
Study 22742205 — intervention group
Group type: EXPERIMENTAL
Intervention: IV montelukast 7 mg and 14 mg
Number of subjects: 242
Study 22742205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 20299485 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg aspirin once daily
Number of subjects: 40
Study 20299485 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg NCX 4016 b.i.d.
Number of subjects: 40
Study 20299485 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of NCX 4016 and aspirin
Number of subjects: 40
Study 20299485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18853112 — intervention group
Group type: EXPERIMENTAL
Intervention: Langchuang No.1 or 2 (Chinese recipes) in addition to Western medicine
Number of subjects: 60
Study 18853112 — intervention group
Group type: COMPARATOR
Intervention: Western medicine alone
Number of subjects: 60
Study 16422913 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg, flexible-dose regimen (5 mg or 20 mg possible after 4 weeks)
Number of subjects: 0
Study 16422913 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 0
Study 16422913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12757990 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 600
Study 12757990 — intervention group
Group type: COMPARATOR
Intervention: Normoglycemic
Number of subjects: 600
Study 12757990 — intervention group
Group type: EXPERIMENTAL
Intervention: Total population
Number of subjects: 600
Study 10391603 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible Laryngeal Mask Airway (FLMA)
Number of subjects: 40
Study 10391603 — intervention group
Group type: COMPARATOR
Intervention: Standard Laryngeal Mask Airway (LMA)
Number of subjects: 40
Study 8887179 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 0
Study 1997509 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (3.2 mg/day)
Number of subjects: 40
Study 1997509 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (0.8 mg/day)
Number of subjects: 40
Study 1997509 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (40 mg/day)
Number of subjects: 40
Study 1997509 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (10 mg/day)
Number of subjects: 40
Study 1997509 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 40
Study 1997509 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose prednisolone (40 mg/day)
Number of subjects: 40
Study 1997509 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose prednisolone (10 mg/day)
Number of subjects: 40
Study 6426828 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (DPA) 400 mg
Number of subjects: 17
Study 6426828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31092654 — intervention group
Group type: COMPARATOR
Intervention: 5% aciclovir cream
Number of subjects: 952
Study 31092654 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical grade kanuka honey (90%)/glycerine (10%) cream
Number of subjects: 952
Study 29408453 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg RAPA daily
Number of subjects: 25
Study 29408453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 27077693 — intervention group
Group type: EXPERIMENTAL
Intervention: STAND (Supporting Teens' Autonomy Daily)
Number of subjects: 128
Study 27077693 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 128
Study 25384211 — intervention group
Group type: EXPERIMENTAL
Intervention: IPPB or LIAM
Number of subjects: 40
Study 23046331 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS)
Number of subjects: 62
Study 23046331 — intervention group
Group type: COMPARATOR
Intervention: Computed tomographic angiography (CTA)
Number of subjects: 62
Study 23046331 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CEUS and CTA
Number of subjects: 62
Study 20133153 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Socioeconomic Status (SES)
Number of subjects: 198
Study 20133153 — intervention group
Group type: EXPERIMENTAL
Intervention: Four SES risk factors (low monthly income, less than a college education, unmarried, unemployed)
Number of subjects: 198
Study 20133153 — intervention group
Group type: COMPARATOR
Intervention: Control for prenatal depressive symptoms
Number of subjects: 198
Study 18358636 — intervention group
Group type: EXPERIMENTAL
Intervention: Flickering stimuli presented in the training phase and filled stimuli presented in the testing phase
Number of subjects: 0
Study 18358636 — intervention group
Group type: EXPERIMENTAL
Intervention: Filled stimuli presented in both training and testing phases
Number of subjects: 0
Study 18358636 — intervention group
Group type: EXPERIMENTAL
Intervention: Filled stimuli presented in the training phase and flickering stimuli presented in the testing phase
Number of subjects: 0
Study 18358636 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 0
Study 16006884 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU vitamin E
Number of subjects: 44
Study 16006884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 12205255 — intervention group
Group type: EXPERIMENTAL
Intervention: SIMV+VG 4.5 (V(T mech) set at 4.5 mL/kg)
Number of subjects: 17
Study 12205255 — intervention group
Group type: EXPERIMENTAL
Intervention: SIMV+VG 3.0 (V(T mech) set at 3.0 mL/kg)
Number of subjects: 17
Study 12205255 — intervention group
Group type: EXPERIMENTAL
Intervention: SIMV+VG 4.5 and SIMV+VG 3.0
Number of subjects: 17
Study 12205255 — intervention group
Group type: COMPARATOR
Intervention: SIMV
Number of subjects: 17
Study 10063823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballistic resistance training (8 weeks of squat jump training)
Number of subjects: 16
Study 10063823 — intervention group
Group type: COMPARATOR
Intervention: Control group (squat and leg press exercises at a 6RM load)
Number of subjects: 16
Study 7723681 — intervention group
Group type: EXPERIMENTAL
Intervention: Nibbling diet (17 meals daily)
Number of subjects: 7
Study 7723681 — intervention group
Group type: COMPARATOR
Intervention: Control diet (3 meals daily)
Number of subjects: 7
Study 2046063 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous TENS (80 Hz)
Number of subjects: 84
Study 2046063 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst TENS
Number of subjects: 84
Study 2046063 — intervention group
Group type: EXPERIMENTAL
Intervention: Modulation TENS
Number of subjects: 84
Study 2046063 — intervention group
Group type: EXPERIMENTAL
Intervention: Random TENS
Number of subjects: 84
Study 2046063 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous TENS
Number of subjects: 84
Study 6352383 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg orally once weekly)
Number of subjects: 155
Study 6352383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 30136597 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital heart rate ⩾100 beats per minute
Number of subjects: 1560
Study 28550255 — intervention group
Group type: EXPERIMENTAL
Intervention: Sembragiline 1 mg
Number of subjects: 542
Study 28550255 — intervention group
Group type: EXPERIMENTAL
Intervention: Sembragiline 5 mg
Number of subjects: 542
Study 28550255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 542
Study 25745496 — intervention group
Group type: EXPERIMENTAL
Intervention: Camel milk
Number of subjects: 20
Study 25745496 — intervention group
Group type: COMPARATOR
Intervention: Cow milk
Number of subjects: 20
Study 25745496 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 23383224 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate potassium (A/CP)
Number of subjects: 11
Study 23383224 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 11
Study 22089970 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (Femara®)
Number of subjects: 2
Study 22089970 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 2
Study 19769010 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 386
Study 19769010 — intervention group
Group type: EXPERIMENTAL
Intervention: Boomers
Number of subjects: 386
Study 19769010 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidities
Number of subjects: 386
Study 19769010 — intervention group
Group type: EXPERIMENTAL
Intervention: Skipping medications
Number of subjects: 386
Study 17680222 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed-dose-rate (PDR) brachytherapy, prescribed reference dose of 49.8 Gy in 83 fractions of 0.6 Gy every hour, total treatment time 3-4 days.
Number of subjects: 105
Study 17680222 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose-rate (HDR) brachytherapy, prescribed reference dose of 32 Gy in eight fractions of 4 Gy, twice daily.
Number of subjects: 105
Study 15197804 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg
Number of subjects: 773
Study 15197804 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 8/4 mg
Number of subjects: 773
Study 15197804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 773
Study 11224833 — intervention group
Group type: EXPERIMENTAL
Intervention: MnCC vaccine (4 doses at 2, 4, 6 months)
Number of subjects: 106
Study 11224833 — intervention group
Group type: EXPERIMENTAL
Intervention: MnCC vaccine (after Dose 3)
Number of subjects: 106
Study 11224833 — intervention group
Group type: EXPERIMENTAL
Intervention: MnCC vaccine (after Dose 4)
Number of subjects: 106
Study 11224833 — intervention group
Group type: EXPERIMENTAL
Intervention: MnCC vaccine (after three doses)
Number of subjects: 106
Study 11224833 — intervention group
Group type: EXPERIMENTAL
Intervention: MnCC vaccine (after booster)
Number of subjects: 106
Study 11224833 — intervention group
Group type: COMPARATOR
Intervention: 7-valent conjugate pneumococcal vaccine (control)
Number of subjects: 106
Study 9679571 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 0
Study 9679571 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 9679571 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical esophagectomy
Number of subjects: 0
Study 7994879 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin depot (3.6 mg) administered monthly for 6 months (n = 22)
Number of subjects: 30
Study 7994879 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin depot (3.6 mg) administered monthly for 12 months (n = 8)
Number of subjects: 30
Study 7994879 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin depot (3.6 mg) administered for 3 months
Number of subjects: 30
Study 2532434 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptation to the climate of moderate altitudes (2100 m above sea level) for 24 days
Number of subjects: 25
Study 2532434 — intervention group
Group type: COMPARATOR
Intervention: Exposure to salt mine microclimate (Chon-Tuz) for 170 hours (days 5-23)
Number of subjects: 25
Study 973959 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (5 mg)
Number of subjects: 0
Study 973959 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (100 mg)
Number of subjects: 0
Study 973959 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (5 mg t.d.s. for 5 days)
Number of subjects: 0
Study 31092647 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU with PCOMS
Number of subjects: 0
Study 31092647 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 0
Study 30423641 — intervention group
Group type: EXPERIMENTAL
Intervention: Wallis implant after lumbar discectomy
Number of subjects: 77
Study 30423641 — intervention group
Group type: COMPARATOR
Intervention: Discectomy alone
Number of subjects: 77
Study 25183203 — intervention group
Group type: EXPERIMENTAL
Intervention: Invited-to-screening arm
Number of subjects: 5852
Study 25183203 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 5852
Study 25183203 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening attendees with positive findings
Number of subjects: 5852
Study 23865402 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive beliefs measured using the MCQ-30
Number of subjects: 77
Study 23865402 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived uncontrollability and danger of thinking (metacognitive belief)
Number of subjects: 77
Study 23865402 — intervention group
Group type: EXPERIMENTAL
Intervention: Beliefs about voices measured using the BAVQ-R
Number of subjects: 77
Study 23865402 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory-II and Beck Anxiety Inventory
Number of subjects: 77
Study 21500885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral analysis system of psychotherapy (CBASP) plus pharmacotherapy
Number of subjects: 491
Study 21500885 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief supportive psychotherapy (BSP) plus pharmacotherapy
Number of subjects: 491
Study 21500885 — intervention group
Group type: COMPARATOR
Intervention: Medication alone
Number of subjects: 491
Study 21500885 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in social problem solving
Number of subjects: 491
Study 19062268 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene
Number of subjects: 2766
Study 19062268 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 2766
Study 19062268 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy (toremifene or tamoxifen)
Number of subjects: 2766
Study 19062268 — intervention group
Group type: COMPARATOR
Intervention: Chemo-endocrine therapy (CMF or AC plus toremifene or tamoxifen)
Number of subjects: 2766
Study 17409581 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiologic study (EPS)
Number of subjects: 474
Study 17409581 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy for heart failure
Number of subjects: 474
Study 15064583 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RTR) 3 times a week for 12 weeks, using three sets of six to eight repetitions at 85-90% 1-RM on lower-body exercises
Number of subjects: 22
Study 15064583 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) performed no resistance training
Number of subjects: 22
Study 11464037 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg apomorphine SL
Number of subjects: 296
Study 11464037 — intervention group
Group type: COMPARATOR
Intervention: 4 mg apomorphine SL
Number of subjects: 296
Study 11464037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study 9732078 — intervention group
Group type: EXPERIMENTAL
Intervention: Force-monitoring platform
Number of subjects: 3
Study 9732078 — intervention group
Group type: COMPARATOR
Intervention: Bathroom scale
Number of subjects: 3
Study 9732078 — intervention group
Group type: COMPARATOR
Intervention: Against a therapist's hand
Number of subjects: 3
Study 8089245 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (0.12%) rinses, 15 ml, 2 times daily for 1 month
Number of subjects: 23
Study 8089245 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution rinses
Number of subjects: 23
Study 3385044 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin therapy (double-blind, controlled, crossover trial in 14 patients)
Number of subjects: 44
Study 3385044 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids
Number of subjects: 44